At this time, I would like to welcome everyone to the International Flavors & Fragrances Third Quarter 2011 Earnings Conference Call. [Operator Instructions] I would now like to introduce Michael DeVeau, Investor Relations Manager. You may begin.

Thank you, operator, and good morning, everyone. With me on the call today is Doug Tough, our Chairman and CEO; Nicolas Mirzayantz, our President of Fragrances; Hernan Vaisman, our President of Flavors; and Kevin Berryman, our Executive Vice President and CFO. This call is being recorded and will be available for playback on our website. Please keep in mind that during this call, we will be making forward-looking statements about the company's performance, particularly with respect to the fourth quarter and full year 2011. These statements are based on how we see things today and contain elements of uncertainty. For additional information concerning factors that can cause actual results to differ materially from forward-looking statements, I ask that you refer to our cautionary statement and risk factors contained in today's 8-K and 10-Q filings with the SEC, as well as our 2010 10-K filed on February 24, 2011. Some of today's prepared remarks will discuss non-GAAP financial information, which excludes those items that affect comparability. These items are laid out in our reconciliation to comparable GAAP measures, which are also available on our website. With that, I'd like to now turn the call over to Doug.

Thank you, Michael, and good morning and good afternoon to everyone. Reviewing our quarterly results, our category, customer and geographic diversity, once again, supported local currency sales growth in the third quarter. Our Flavors business, led by our health and wellness portfolio and double-digit growth in the emerging markets, continued to outperform the industry and gain market share. In Fragrances, results were pressured by a challenging year-ago comparison, price-driven volume declines in Ingredients and a general weakening of our more discretionary categories, such as Fine Fragrance & Beauty Care. Focusing specifically on Ingredients, sales declined 15% year-on-year, as price increases to protect margin had an adverse effect on our volumes. The impact on our top line performance was pronounced, roughly a 300 basis point drag on Fragrance sales and a 150 basis point impact on total company sales growth, as Ingredients accounts for approximately 20% of Fragrance sales and 10% of overall total company sales. It should also be noted that while we communicated in early September that we expected Q3 sales growth would be similar to Q2 levels, macroeconomic and global market instability throughout the month hurt overall volume performance in our discretionary categories. Fortunately, from a profitability perspective, the discipline of our organization in the areas of pricing and cost control continue to yield benefits. While gross margin was under pressure due to higher-than-anticipated raw material cost, we were successful in achieving sequential improvements in pricing, over 3 percentage points during the quarter, and again captured the benefits from our European restructuring. In addition, our cost discipline, including the benefit of lower incentive compensation accruals and favorable foreign exchange, allowed us to deliver a 4% increase in adjusted operating profit and a 2% year-on-year increase in adjusted earnings per share. While quarterly results are important scorecards, performance over…

Thank you, Doug, and good morning and good afternoon, everyone. Compared to a 15% increase in the prior-year period, local currency sales declined 5%, as new business wins and pricing benefits were more than offset by volume declines on existing business. It should be noted that while volume declines on existing business are typical in the Fragrance industry due to the evolution of the portfolio, the year-over-year decrease this quarter was greater than historical averages, as we compared to the 2010 period, where volumes were actually up. In Fine Fragrance & Beauty Care, local currency sales declined 4% against a very strong 24% growth rate in Q3 2010, as new business wins and price increases were more than offset by volume declines with existing customers. Our EAME and Latin America regions were once again pressured the most, as we cycled a 20% growth rate in EAME and a 54% growth rate in Latin America in 2010. Volume growth on existing business in these regions was very strong in Q3 2010, causing significant year-over-year pressure this year, particularly in Latin America, where volumes were up an unprecedented 20%. Functional Fragrance results were similar to year-ago level, as new business wins, the realization of price increases and continued success in the Home Care and Fabric Care categories balanced out volume declines. From a geographic perspective, North America continued to perform well, growing 3%, as Home Care achieved very strong double-digit growth. Fragrance Ingredients was most challenged, as we took strategic price increases to protect margin from rising raw material costs. Unfortunately, the adverse effect on volume was greater than historical correlations and, therefore, had a greater impact on our results. It should be noted that top line performance for our Fragrance compound business, which exclude the 300 basis point drag of Ingredient…

Thank you, Nicolas, and good morning and good afternoon, everyone. Marking the 25th consecutive quarter of growth, I'm happy to report that local currency sales in the third quarter grew 8%, led by double-digit increase in Savory and a high single-digit increase in Beverage. In North America, our capabilities in sodium and sweet modulation once again drove high single-digit growth, a trend that has been ongoing for 6 straight quarters. For the 7th consecutive quarter, our EAME region continued to achieve at least big ]ph] single-digit growth. Once again, within the region Eastern and Central Europe, Africa and the Middle East, all grew strong double digits. Western Europe also posted growth, as our innovative naturalist portfolio continued to provide us with a competitive advantage to win key new business. In Latin America, all categories were positive, led by double-digit growth in Confectionery and Savory. On a country level, it's worth noting that we have seen trends in Mexico deteriorate relative to first half performance, as consumers are being impacted by the economy. Fortunately, our results continue to be strong, led by our geographic diversity, as countries like Brazil, our largest Latin American market, grew double digits. Last, but not least, our best performing region in both dollar growth and percentage change was Greater Asia. Performance in these regions sequentially improved from the second quarter, growing 10% at every category reported strong growth, highlighted by Beverage, where we achieved high double-digit growth. Consequent with the previous 2 quarters, the impact of exiting low-profit business in the third quarter was approximately $1.5 million. Going forward, it should be noted that we plan to exit additional business, specifically in 2012, as we believe exiting certain underperforming business is our best option to maximize shareholder value. I expect the impact of exiting these business will be greater than what we exceeded throughout 2011, and therefore believe that the quality of our sales growth going forward will be better as we further develop our more profitable businesses. For the 8th consecutive quarter, our emerging markets business continued to grow double digits. This performance was driven by the BRIC countries, including one extra eye for Indonesia where each country achieved a double-digit growth rate. Turning to profits, third quarter operating profit increased 13% or $8 million to $71 million as accelerated sales, including volume growth and pricing that's continued cost discipline drove results. Operating profit margin declined 10 basis points versus the previous year to 20.9%, as pricing actions and cost control initiative virtually cover the impact of higher raw material costs. Looking ahead, we have started the fourth quarter well, led by strong new business wins. Pricing initiatives should help to reduce the impact of raw material cost, and we expect that our focus on controlling costs should allow us to sustain momentum and finish 2011 with strong operational performance. With that, let me turn it over to Kevin.

Thank you, Hernan, and good morning and good afternoon, everyone. Third quarter 2011 sales totaled $714 million, an increase of 6% from the prior year period as the impact of foreign exchange contributed positively to our top line growth. The emerging markets continued to perform well, up 4% on a local currency basis. Adjusted operating profit grew 4%, or $5 million, to $128 million, while gross margin contracted 330 basis points as a result of the significant increases in raw material costs. Adjusted operating profit margin only declined by 40 basis points to 17.9% versus 18.3% in the year-ago period as we continue to exhibit strong cost control and benefit from lower incentive compensation accruals. The end result was adjusted EPS grew 2% year-over-year to an even $1 figure. Evaluating our gross margin performance in greater detail, I thought it would be helpful to discuss the drivers of year-over-year change relative to our Q2 results. It was our expectations on our Q2 conference call that gross margin would remain under pressure, although to a lesser extent, and what we experienced in the second quarter. Our forecast was predicated on raw material cost increases being similar to Q2 levels. And when combined with greater pricing benefits, would reduce the margin GAAP and show sequential improvement in gross margin versus the second quarter. The shortfall to our expectation can be attributed to higher-than-expected raw material costs in the quarter and a reduction in volume, which reduce the benefits of expected absorption in our factories. The combined impact of these items resulted in a shortfall in gross margin of approximately 200 basis points versus our original expectation. Pricing benefits did accelerate as expected, rising from 2% in the second quarter to over 3% in the third, as the team was successful in securing…

Thank you, Kevin. Looking towards the fourth quarter, we expected the Flavors trends to remain strong, driven by our health and wellness portfolio and the emerging markets. Fragrance sales are expected to remain under some pressure, as we continue to experience price-driven volume declines in Ingredients, although improved versus Q3, and some softness in our more discretionary categories, such as Fine Fragrance. While we continue to expect greater pricing benefits in the fourth quarter, the gap between raw material costs and price increases is expected to remain. When combined with the reduction in our Fragrance volume outlook, gross margin in the fourth quarter is expected to decline versus Q3 levels. Nevertheless, we will continue to focus on controlling costs in quarter 4 to drive operational performance above our 7% to 9% operating profit growth target, which is expected to lead to a year-over-year improvement in operating profit margin. It should be noted that despite our strong profit performance, Q4 earnings per share will be challenged, as we will compare to a lower effective tax rate of 21.1% in the prior year period. On a full year basis, given our year-to-date performance plus our more cautious outlook for Q4, we now expect local currency sales and adjusted earnings per share growth to approach the lower end of our long-term ranges. Despite the headwinds previously mentioned, we continue to believe we can deliver adjusted operating profit growth above our long-term targets, driven by our efforts in pricing, the benefit of previous restructuring activities and cost control initiatives. In summary, we are pleased with our year-to-date performance in light of the challenging operating environment and the exceptional base period established last year, where we grew 14%. Upon entering 2011, the environment in which we conduct business was very different relative to where we are today. Unprecedented raw material cost increases, consumer concerns, global economic uncertainty and foreign exchange volatility. As such, I would like to acknowledge the IFF team ability to adapt both strategically and operationally during difficult times to deliver these solid results. As we look forward, we are cautiously optimistic and confident that our business, supported by a culture of excellence, will remain strong, and that our financial results will provide strong returns for our shareholders longer term. In times such as these, diversity is a compelling characteristic. Fortunately, the wide variety of products that we sell across many countries around the world to the thousands of customers we have helps us remain confident in our ability to deliver our financial targets longer term. We expect that we can continue to enhance our performance as we make progress against the strategic plan. By leveraging our geographic reach, strengthening our innovation platform, maximizing our portfolio, we believe we can drive commercial performance that will lead to greater shareholder value. Thank you for your attention. With that, we will be happy to take any questions that you may have.

[Operator Instructions] Your first question comes from Mark Astrachan with Stifel, Nicolaus. Mark S. Astrachan - Stifel, Nicolaus & Co., Inc., Research Division: So on fragrances, the Fragrance trends seem to be getting substantially worse on a 2-year basis. And even if fourth quarter results improved slightly, it seems it will worsen still. So I guess, the question is, it seems there's something wrong here beyond tough comparisons? So curious if you can elaborate on the competitive dynamics in the category and what seems to be the cause of IFF's seeming underperformance here?

Art, it's Nicolas. As I say in my prepared remarks, our Fragrance business has been impacted by price-driven volume declines in Ingredients, which is really one of the key area where we saw the pressure. It's an area where we took strategic and proactive pricing to protect margins long term. What we anticipated is pricing actions will have an adverse effect on our Ingredient volumes. The downside pressure was greater than what we have seen historically. Actually, it's 3 points of volume for every point of price. In the rest of our business, we have seen volume on existing business slow due to weaker volume trends associated with the very strong year-ago volume comparison, especially if you look at Q3, but if you bring it down to the first 9 months, we still have positive dynamic. We see also some customers, which are more cautious in their stances, really talking about the uncertain economic environment and being also cautious about inventory and also potential impacts from higher pricing. So if you look at the 2-year, we're still -- 2-year period, we're still in a positive position. Some pressure in Q3, but otherwise, in my remark, if you look on the compounds for the first 9 months, we're positive in the compound business against very, very strong comparables. Mark S. Astrachan - Stifel, Nicolaus & Co., Inc., Research Division: I guess, just to build on that, in all due respect, we're mostly through earnings at this point. And from an HPC universe standpoint, you haven't really heard any companies talk down expectations in terms of their own ordering or inventory levels or anything like that. And on top of it, the Flavors business, maybe it's taking less pricing? But it seems that Hernan and his team are taking pricing there as well, and you're still seeing pretty positive results out of -- in the business. So I guess, I'm still not quite clear what's going on from a competitive standpoint here? Is it something unique to IFF where basically your competitors took a lot less pricing and as you're losing share and maybe at some point that reverses itself? But beyond the comparisons, it's not getting better.

Mark, this is Kevin. Just to augment some of the things that Nicolas talked about. We did take, as you suggested in your question, the pricing fairly proactively in the first initial stages of 2012 -- excuse me, 2011. And certainly, that has impacted the Ingredients business that Nicolas has already referred to in his commentary and his response to the question. So there clearly is a dynamic there that is affecting the volume characteristics of that business. At some point in time, we will get through the pricing implications as it relates to that. And we do fundamentally believe that the price stances that have been taken for that business are holistic and appropriate as it relates to ensuring we have the appropriate margin profile going longer term. So that's one point. I also think that if you look at the kind of the 2-year, we still are at rates that are above the growth for the category. And so, yes, while we're seeing a deceleration versus the very strong numbers that we saw a year ago, that's just a natural -- from my perspective, at least a portion of it, is a natural progression of the working through the numbers that were so strong year ago. So the 2-year numbers still are indicative of on a year-over-year basis that we'll be able to gain share versus the overall industry. And we'll have to see how we play out over the course of the balance of this year and through 2012.

Your next question comes from Ed Aaron with RBC Capital Markets.

I was just interested in your commentary about a new flavor technology that might be coming for 2012. Just how would you manage your expectations around that and the potential impact that we might see in that business over the next year or 2?

It's Hernan here. While we are in the process of revalidating this technology we'll be launching officially in the first quarter, we see really very good and positive -- we have very positive expectation, but will be seeing ramping out -- ramping up I mean, the business more strongly in 2013.

Okay. And then just wanted to follow up just incentive compensation. It was obviously a pretty low number this quarter. Just trying to think through to 2012, what type of headwind do you anticipate for next year, assuming you hit your plan next year in terms of your headwinds of growth in 2012 as a result of the light incentive comp payments this year?

We're not going to comment a lot on 2012 at this particular point in time. We will see if, in fact, to -- if things don't materially change, we'll see a headwind as it relates to the reset of incentive comp next year. We'll give -- we'll provide more details on that when we give the specifics relative to our final Q4 numbers, as well as the outlook for 2012, though. Yes.

Your next question comes from Lauren Lieberman with Barclays Capital.

I don't want to beat a dead horse. But I think the question that we're trying to ask about the Fragrance business at this point is not really about Ingredients. I think there are questions there, but we kind of get the volume and pricing issue. But on a 2-year basis, there was a very significant deceleration in both Fine and in Functional this quarter. Still positive, yes, but definitely, deceleration. So while the 9 months are great, I'm more concerned about going forward. So looking forward, should we expect things to continue to decelerate? If so, why are win rates decelerating? Are the existing volumes falling off more quickly than would typically be the case because maybe the commercialized products aren't getting the kind of market share and performance that was the case a year or 2 ago? I mean, there's something -- something does feel different, and that's what I'd love to get some help understanding.

Lauren, let me make some additional commentary on that, hopefully, to help you look there is clear that the volume on our existing business has shown some incremental softness versus what we have seen in the past. That's clear. Our wins continue to hold up consistent with the levels that we've seen in the first -- over the last couple of quarters, as a matter of fact. So what it really is, is some volumes that we have seen in terms of our existing business. And so, certainly, as Nicolas talked about, some of that is relative to the strong comparable. Some of it could perhaps be about some of the pricing actions that we took and various other things that Nicolas has already talked to. But I think that's what we can comment on at this particular point in time.

Okay. And is there anything -- and I'm glad since, Kevin, you mentioned pricing. Is there anything that should suggest whether you're not seeing -- I know it's not direct comparisons to competitors when you get into the compound business, but you guys have been talking about pricing with your customers for a very long time at this point. In theory, kind of getting ahead of the curve on cost inflation or at least getting your customers more ready for the pricing. And yet maybe it feels like there was a little bit more openness to pricing, but there's more elasticity than you would have expected even outside of Ingredients? So does that alter your thought process maybe, Kevin or Doug, on the go-forward plans you guys have for pricing and improving the profitability of those under performing parts of the portfolio via pricing?

Lauren, it's Doug. A couple of points. Just touching off the final -- or another point. We've not, on the Fragrance business, we've not seen any material changes in core listing and, in fact, have had some gains, which gives us more confidence going forward. So some of your questions or issues are well founded. We're digging into the facts, too. But as you drill down the various elements that could be a part of it, certainly, the opportunity for core listing is key, and there's only good signs there. On your other point and the more important one, I mean, I think we were ahead of the curve on both pricing actions. But at the time, we took some of that pricing actions, these conversations now going back better part of 12 months, they were all earmarked around pricing or cost expectations in the mid-single digits and the creek continued to rise, if you will, throughout the year necessitating follow-up rounds of pricing. And as Kevin mentioned a few moments ago, we now expect for the full year the cost impact from raw materials perspective on the company is going to be 10% or roughly double what we first envisioned. So that has necessitated taking pricing. So -- and we will continue to do so. And against the expectation of margins to enable us to invest in the business, we will need to continue to come back and take pricing not only on those parts which may be disadvantaged in order to rectify the situation, but also on the core product portfolio. So if prices continue -- if Ingredients continue to go up next year as we expect they will modestly, we will need to engage our customers to price to recover that.

Your next question comes from Jeff Zekauskas with JPMorgan Chase. Jeffrey J. Zekauskas - JP Morgan Chase & Co, Research Division: You spoke about your raw materials being up 13%. If -- if you look on the Fragrance side and you break things up into your feedstocks, your naturals and your petrochems, were they all up roughly 13%, or was there a real variance between the different components? And for your Ingredients business, which is most important, the petrochems, the naturals or the turpentines?

Jeff, it's Nicolas. When we look at the different dynamics in our input costs, you have great variations. So were the numbers you were related to was really the aggregate of everything. So we have some parts of the feedstock where we saw the greater pressure than the 13%. And to come back to your second question, for Ingredients, obviously, turpentine is a key components of it, but also petrochemical is also a key drivers. Jeffrey J. Zekauskas - JP Morgan Chase & Co, Research Division: So basically, what's happened over a short period of time is that benzene costs have really come down. Propylene has really come down, just a wide variety of petrochemicals. So do you read the fall in your volumes, which seem incommensurate with general industry numbers, as customers saying, "Oh, we see raw materials coming down, what we want to do is we want to buy in the future at lower prices?"

If you look at the portfolio, they are still above the previous period. So we still see additional pressure, as Kevin was mentioning, going into next year. And I think that we need to look at which are the key leading indicators to understand why is the movement on feedstock, as some have been showing maybe some reduction in the increase, but still at above level of 2010, 2011. So we see continued pressure going into this.

Just a few additional comments. What we are seeing is the numbers for input costs, while they're slightly up versus where we have been talking, and certainly, as Doug suggested, significantly up versus 12 months ago on what our expectations would've been back then. What's happened is that the costs have remained relatively elevated and versus where we are in the markets, that's what has surprised us ultimately, which is translating into the input costs being a little bit higher. And I think that as Doug has suggested, we'll look to take the pricing necessary to continue to cover those incremental costs. Jeffrey J. Zekauskas - JP Morgan Chase & Co, Research Division: And then lastly, from the consumer products companies, there seems to be some sort of voicing of the idea that they should reduce the number of new products that they put out. And normally, volume growth in Flavor and Fragrances or in Fragrances really coincides with new product introductions by your customer base. Can you talk about whether their volume of new product introduction seems to be accelerating or decelerating or staying the same?

We have not seen a deceleration. Actually, we're seeing sometimes, maybe fewer brands, but bigger brands. And we are seeing brands trying to expand into new geography or brands trying to expand into new categories, representing additional opportunities [ph] for us. So we have not seen on the aggregate a deceleration. And as a matter of fact, we have gained access to more business available to us by gaining access to new core list, and now we're seeing the amount of projects on which we're working moving forward the absolute dollar value being greater than last year at the same period.

Your next question comes from John Roberts with Buckingham Research.

Can you -- or do you have any gut feels for at least if any of this is inventory or channel correction in the Fragrance business? And do you think the strength in the past several quarters was some inventory building?

I think that we saw an acceleration in Q1. We're way above the market. Way above the category or market growth. So it is possible that people have build to a -- to build inventory for the year. But lately, what we're seeing is that people are actually more cautious for the future, and they want to make sure that they are managing their inventory, managing their working capital. It's probably affecting some categories more than some others. And that's what we're seeing across the portfolio.

And typically, how long would an inventory correction last?

I mean, I think it's very difficult to see because we're coming from 2 extreme years, 2009, where you have so much destocking; 2010, when we saw restocking. So it's very difficult right now to make any assumption in terms of the different cycles.

Okay. And then last question was, Doug, I thought that exiting of products was sort of the last of your plans, the first was the price increases. If customers didn't take pricing, then you would offer them reformulated or lower cost alternative product. And then as a final option, exiting. So does that mean you've exhausted the pricing and reformulation lower alternative options and exiting is what's left?

In a couple of cases, John, that has been the case for the $4 million that we've mentioned. Now you're right in terms of the gradient of trying to work with a customer to understand the situation and the profitability and then reformulation. We'll continue to do those. And I expect that there's going to be ultimate outcomes on each of those options. But they're concluding option 3 where if it is a low value added, and we don't have a competitive advantage, and the customer has a cheaper opportunity that's not giving us the margin that we need, there will be some businesses that we would readily exit.

So how much of the $50 million that was targeted has been captured so far in the first 2 options?

Well, the $50 million was a holistic response to the strategic options. And as we've said, it's a small part at this time. But the exiting the business and so on, that is a very small, small part of that total profitability improvement.

Your next question comes from Mike Sison with KeyBanc.

In terms of the product rationalization efforts heading into 2012, Doug, could you give us an idea, it was $4 million this year, does it double, triple, quadruple as we head into next year?

A lot of that is going to come from the Flavors business. So I'll ask Hernan to talk to that.

At this point in time, we would not, I mean, open this kind of information. But as I mentioned in my scripts, I -- we believe that we will be much higher than we have today. We will not open any time because we are still negotiating with customers and we haven't finalized, I mean, the decision of exiting or not. But I can tell you that it was much higher than what we have so far in 2011.

Okay. And then, Kevin, the 15% decline in Ingredients' local currency, was that pretty much all due to pricing? Or was it half, was it 3/4? Could you give us an idea of the degree of the hit?

Well, at the end of the day, if you have a volume decline, it's not exactly clear what's going to be driven by your price. But we took a very proactive stance on those pricing initiatives. So as we've talked about, there was a 3:1 ratio as it relates to our pricing versus volume. So it certainly was a big part of it.

And that would continue -- that degree would continue in the next couple of quarters unless you lower the price to get the business back?

It would depend upon other players in the industry and what their pricing stances are. We feel good about our pricing as it relates to the holistic perspective of ensuring we have the appropriate margin profile going forward.

Got it. And then, Nicolas, when you think about 2012, how is the backlog of project wins and the major areas, Fine and Beauty and Functional as you head into next year? Is the backlog the pretty good? Is it smaller or bigger?

The backlog is very good and also not just for 2012, but also for 2013, where we've been able to already secure some significant projects that will flow into 2013. So I see the win rate is still very strong. And not only is still very strong, but we have access to more business by gaining access to new core listing and getting access to brands we're expanding.

Your next question comes from Erik Sjogren with Morgan Stanley.

It's Erik from Morgan Stanley. Just a quick question on the pricing. Is there a point where you would start rolling back the pricing? Or is it simply that your peers are not following so you feel that the volume declines have become too big, so to say? I think you seem to be saying that you will be taking pricing also in the fourth quarter. But is there a point where you would start to reevaluate them?

Certainly. on Ingredients, Erik, I think that's a possibility, depending upon the feedstock implications and the input costs. Certainly, on -- where we talked a lot about the need for further pricing, it's conceivable. It's in that area. But it's more conceivable on the more traditional formulas we have in Flavors and in Fragrances, where there -- the key Ingredients there would necessitate pricing. So where it's a function of a commodity, we'd have to recognize the market, and that's what we did in our initial pricing actions, but on our core formulas with products, we would continue to take pricing. And there's just one little caveat I'd like to go back and touch upon, and that was really in response to the softness and so on. We lost some business to competitors that were pricing it at lower levels in anticipation of their ability to get some -- the product supply. In some cases, that's now appearing perhaps not to be the case in some of the business that we lost to lower-priced competitors. Some of those customers are now coming back and inquiring about the availability of supply. So, I mean, we stand by the strategic moves we've made and because they're pricing and shareholder-driven. But if we have to adjust prices on some of the items, which are commodities, we'll certainly consider that.

Your next question comes from Alec Patterson with RCM.

I guess I'm just trying to get a little bit of a handle on the amount of pricing that you guys were targeting sort of mid-summerish where I think you talked about -- it was the second round of pricing that you were going into with your customers. And you had sort of a visibility on higher raw materials. Certainly, double-digit levels running to the second and third quarters. And did you get the level of pricing that you expected you'd needed to sustain and improve in gross margin trend, or did you -- or did it end up coming in less maybe because you recognized greater elasticity than you thought? Or I'm just wondering to what degree you were able to actually capture your original goals on your original pricing assumptions?

This is Kevin. I'll take a crack at that. Look, I think we certainly have taken pretty significant pricing over the course of the year. And as discussed, we have a 3% number in the period. But keep in mind -- in the quarter, excuse me, keep in mind, that we did see a slight elevation in the input costs that flowed through the P&L in Q3. So we lost a little bit there, and I've already described that in the presentation. The other point that I think is important to note is we would have originally thought that in the first -- when we were talking around the midpoint of the year, that we get some additional pricing that was flow through in Q4. Some of that is actually happening, and some of it will end up benefiting us in Q1 of next year. That's probably the change from where we were at the mid-year point.

But the pricing that you had in the second round, was it sufficient to cover the level of raw materials the was evident as of the second quarter, the second quarter where you had a 12% increase? Other words, were you able to at least get the pricing to cover that in this second round?

We were very close to having pricing in place by the end of the year relative to what our expectations on input costs were at that point in time. I would say 90% plus. We're little bit light of that, given the higher levels of input costs. And consequently, some of the pricing actions that we've been discussing are going to end up occurring in the first quarter of next year to ensure that we have the ability to cover those incremental costs.

Okay. I mean, I understand that because, obviously, pricing, for everybody, has been a challenge. And I was just wondering, as you recalibrated the elastic response, your elasticity models must be coming up with new results given this new set of data that's come in. Is this having an impact, do you think, on how you look at your long-term financial targets, given the potential volatility of raw materials over time?

I'll take a crack again. I don't kind of think that we would necessarily see that as an issue at this point in time. We certainly are in a volatile situation given the input cost dynamic that we've been facing and the strong pricing that we've taken, specifically on the Ingredients business. And I think Doug has already addressed how we would see ourselves addressing pricing going forward on the Ingredient business. And I think that if we saw some reductions in input costs, we certainly would consider that within the Ingredients business on some of the lower value-added items that are in the portfolio.

Okay. But the trade-off on pricing versus volume isn't -- the breadth of the portfolio has not changed significantly enough given this recent experience to alter your longer-term sales growth outlook?

That would be correct.

That's correct.

Your next question comes from Mark Astrachan with Stifel, Nicolaus. Mark S. Astrachan - Stifel, Nicolaus & Co., Inc., Research Division: On your full year outlook, it sounds like you're anticipating a bit of an improvement in the fourth quarter, particularly from a sales standpoint. I guess I'm curious why that's the case given the September trends seem to have worsened from July or August? And then curious if you could give some color on what October look like? And if you could set of parcel it out by pricing because we know that's obviously going up, and what the impact would be on volumes, that will be helpful, too.

I think as Hernan has already talked about, October started strong in the Flavors business. And I would say that we haven't seen any worsening through October as it relates to the Fragrance top line. And we'll, obviously, continue to monitor that. I think that what we said is that the full year number of 4% is pretty close to our year-to-date figures as it is. So that doesn't imply a big swing one way or the other as it relates to what Q4 might look like. I mean, we're in rounding numbers here, Mark.

Your next question comes from Lauren Lieberman with Barclays Capital.

Just on Ingredients. Our understanding is that your -- one of your larger competitors has started to raise pricing in Ingredients. And I know that we all talked about second quarter there being that lag and that was probably part of why some share was lost there. So why -- I mean, you may not have done this sort of digging in yet, but why do you think it seems that the, I guess, the relative performance of your Ingredients business versus theirs, it got worse this quarter? I would have thought that share losses would have stabilized if everyone is now operating with a similar price list. But it seems like it's gotten worse?

Lauren, it's Nicolas. First of all, it's important to underscore the we have very, very different portfolio. So the makeup of portfolio is very different and the portfolio as to deals related to input costs. And therefore, some of our portfolio required a greater level of ingredients in marketplace. We have also very different competitors in the different portfolio in which we compete. So it's very, very difficult to go for like-for-like. And we are sometimes in very, very different types of portfolio.

Okay. And that's particular to the Ingredients portion of the business?

Correct. That is correct. And also, if you look at some of the dynamics and what has captured some of the specialty Ingredients also include some Flavors Ingredients. So the numbers are also more difficult to compare.

Okay. So with the, what you can see, I guess, and what I can't see in terms of competitor activity in more -- with more compatible portfolios, do you have the sense that your competitors have now started, have followed or put the pricing through so that, that rate of share loss should stabilize?

It's very difficult to have visibility and difficult to comment on what they're planning to do. I think that as we can read in the industry, all across, everybody is facing the same input cost pressure, so you expect people to adjust and adjust their strategy according to it. But it's very difficult to comment from what other people will be doing.

Your next question comes from John Roberts with Buckingham Research.

Yes, I wanted to come back to this $50 million profit improvement program again. So if exiting products is a relatively small part of that, again, I would have guessed you'd taken much of the actions on price and reformulation already? But it doesn't sound like you've achieved a significant part of the $50 million yet.

That would be correct. And certainly, some of the pricing that we had taken in anticipation of improvements was taken and was frankly subsumed by the raw material cost increases that were higher than we first thought. And to a degree, we took one step forward, and we took one step backward and have to revisit all those discussions with customers, and we're doing so. But the other parts of the profit of that improvement plan really flow out of some of the strategic initiatives we are taking in R&D and in penetrating new geographies and new markets, and those will be the catalysts for the lion's share of that growth.

So the pricing that you still have to take on those products that are underperforming, you still feel good about being able to achieve that? Because obviously, those were once that -- it wasn't just the raw material cost increase, that was something where you were trying to get your margins up on the business. So those customers you think will take more price?

Well, I think we -- the challenge we all have, John, and it will be a challenge, but it's a challenge we have to take up, is to go to those customers and explain with facts and data and rationale and specific pricing, where we are, and the unacceptable position we are in and the need to negotiate those prices. So that challenge which was there last year and was taken up positively with the team, then the benefits of that were lost to the higher pricing that we encouraged to near [ph], so we go back and take a swing at again.

There were no further questions.

Thank you very much for your participation today. We're adjourned.

This concludes today's conference. You may now disconnect.